NCT06613256 Characterisation of Endothelial Cells in Different Inflammatory Pathologies
| NCT ID | NCT06613256 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Royal Surrey County Hospital NHS Foundation Trust |
| Condition | Sepsis |
| Study Type | OBSERVATIONAL |
| Enrollment | 105 participants |
| Start Date | 2024-07-16 |
| Primary Completion | 2026-07-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 105 participants in total. It began in 2024-07-16 with a primary completion date of 2026-07-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to characterise changes in gene expression in endothelial cells in patients with either sepsis or post major abdominal surgery. The main question we plan to answer is: 'What molecular pathways are differentially expressed during inflammatory pathologies?'
Eligibility Criteria
Inclusion Criteria: Healthy volunteer * Adult ≥ 18 years * Able and willing to give consent Surgical patients * Adult ≥ 18 years * Patients admitted to RSFT for planned major surgery Critically ill patients * Adult ≥ 18 years * Emergency admission to ICU at RSFT * Meets the sepsis 3.0 definition Exclusion Criteria: Healthy volunteer * Not currently a patient within the hospital * Absence of inflammatory diseases and disorders including but not limited to arthritis, peripheral artery disease, vasculitis, diabetes, cardiovascular disease and CKD. * Not on immunomodulatory medications, such as corticosteroids * History of recent major trauma within the last 2 months (e.g., surgery or injury requiring hospitalisation) Surgical patients * Patients with restricted liberty, prisoners or under legal protection * Anticipated prohibitively difficult venous cannulation * Presenting with inflammatory diseases and disorders including but not limited to arthritis, peripheral artery disease, vasculitis, sepsis, diabetes with end organ damage, cardiovascular disease and CKD * Currently prescribed immunomodulatory medication or immunocompromised * Received chemotherapy within 2 weeks of predicted sampling * Receiving vasopressor support prior to surgery * History of recent major trauma within the last 2 months (e.g., surgery or injury requiring hospitalisation) Critically ill patients * Patients with restricted liberty, prisoners or under legal protection• Anticipated prohibitively difficult venous cannulation * Presenting with inflammatory diseases and disorders including but not limited to arthritis, peripheral artery disease, vasculitis, diabetes with end organ damage, cardiovascular disease and CKD. * Currently prescribed immunomodulatory medication or immunocompromised * Received chemotherapy within 2 weeks of predicted sampling. * History of recent major trauma within the last 2 months (e.g., surgery or injury requiring hospitalisation)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06613256 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06613256 currently recruiting?
Yes, NCT06613256 is actively recruiting participants. Contact the research team at bencb@nhs.net for enrollment information.
Where is the NCT06613256 trial being conducted?
This trial is being conducted at Guildford, United Kingdom.
Who is sponsoring the NCT06613256 clinical trial?
NCT06613256 is sponsored by Royal Surrey County Hospital NHS Foundation Trust. The trial plans to enroll 105 participants.